background
administr
convalesc
plasma
may
clinic
benefit
treatment
sever
acut
viral
respiratori
infect
howev
clear
evid
exist
support
oppos
convalesc
plasma
use
clinic
practic
conduct
systemat
review
metaanalysi
assess
evid
random
control
trial
rct
convalesc
plasma
treatment
sever
influenza
method
healthcar
databas
search
februari
record
screen
elig
criteria
data
extract
risk
bia
assess
undertaken
primari
outcom
casefat
rate
influenza
result
identifi
rct
sever
influenza
pool
analys
show
evid
reduct
mortal
odd
ratio
confid
interv
ci
p
also
found
nonsignific
reduct
day
icu
hospit
day
mechan
ventil
seem
biolog
benefit
increas
hai
titer
level
decreas
influenza
b
viru
load
cytokin
convalesc
plasma
treatment
seriou
advers
event
report
two
group
studi
commonli
low
risk
bia
high
qualiti
conclus
convalesc
plasma
appear
safe
may
reduc
mortal
sever
influenza
therapi
studi
within
context
welldesign
clinic
trial
treatment
infect
cr
convalesc
plasma
studi
g
effect
convalesc
plasma
hyperimmun
immunoglobulin
treatment
sever
acut
respiratori
infect
viral
etiolog
systemat
review
exploratori
metaanalysi
j
infect
di
viral
pneumonia
major
caus
morbid
mortal
around
world
caus
organ
viral
pneumonia
vari
greatli
emerg
sever
acut
respiratori
syndrom
coronavirus
sarscov
avian
influenza
viru
middl
east
respiratori
syndrom
coronavirus
merscov
play
import
role
caus
sever
pneumonia
success
attent
turn
novel
coronaviru
sinc
decemb
increas
number
case
pneumonia
infect
report
china
knowledg
effect
antivir
infect
current
approach
clinic
manag
gener
support
care
provid
critic
care
organ
support
necessari
suggest
administr
hightitr
antiinfluenza
immun
plasma
deriv
convalesc
immunis
individu
may
yield
clinic
effect
treatment
season
pandem
influenza
viral
etiolog
report
convalesc
plasma
treatment
reduc
hospit
stay
mortal
patient
sarscov
infect
sever
influenza
furthermor
systemat
review
studi
use
convalesc
plasma
also
found
evid
clinic
benefit
patient
therefor
convalesc
plasma
may
promis
patient
infect
particularli
present
critic
ill
howev
underli
evid
base
previou
studi
poor
qualiti
random
trial
recent
random
control
trial
shown
convalesc
plasma
hyperimmun
intraven
immunoglobulin
hivig
prepar
pool
plasma
obtain
convalesc
patient
confer
signific
benefit
placebo
patient
influenza
infect
contrast
previou
studi
therefor
conduct
systemat
review
metaanalysi
evalu
clinic
efficaci
either
convalesc
plasma
hyperimmun
immunoglobulin
treatment
sever
influenza
help
inform
clinic
manag
infect
includ
prospect
random
control
trial
rct
involv
patient
influenza
treat
convalesc
plasma
hyperimmun
immunoglobulin
limit
public
english
languag
exclud
crossov
trial
beforeaft
studi
confer
present
abstract
public
case
report
editori
case
seri
studi
compar
also
exclud
two
review
zhx
jmz
execut
search
strategi
februari
increas
sensit
search
strategi
combin
term
influenza
convalesc
plasma
convalesc
serum
hyperimmun
immunoglobulin
immun
plasma
hivig
key
word
medic
subject
head
mesh
term
search
databas
pubm
embas
scopu
web
scienc
electron
databas
incept
februari
systemat
screen
abstract
full
text
public
studi
met
elig
criteria
studi
popul
interest
patient
age
sex
hospit
influenza
laboratoryconfirm
viral
infect
intervent
convalesc
plasma
serum
hyperimmun
immunoglobulin
deriv
convalesc
immunis
individu
compar
treatment
includ
placebo
low
titr
plasma
sham
therapi
primari
outcom
review
casefat
rate
influenza
reflect
efficaci
convalesc
plasma
hyperimmun
immunoglobulin
therapi
secondari
outcom
includ
antibodi
level
cytokin
level
viral
load
incid
seriou
advers
event
day
mechan
ventil
icu
hospit
two
investig
zhx
jmz
independ
review
abstract
data
retriev
articl
supplement
discrep
resolv
discuss
consensu
assess
qualiti
includ
trial
base
review
detail
method
section
supplement
includ
trial
apprais
trial
qualiti
use
cochran
collabor
tool
assess
risk
bia
rob
includ
assess
random
sequenc
gener
alloc
conceal
blind
intervent
outcom
measur
assess
incomplet
outcom
data
select
report
bia
potenti
sourc
bia
eg
industri
fund
criterion
apprais
rob
either
low
high
unclear
risk
eg
insuffici
detail
two
author
zhx
jzm
independ
assess
studi
qualiti
disagr
resolv
consensu
use
statist
evalu
impact
heterogen
pool
result
valu
greater
indic
substanti
heterogen
use
fixedeffect
model
pool
data
heterogen
insignific
random
effect
model
pool
data
signific
heterogen
identifi
categor
data
pool
use
odd
ratio
or
confid
interv
ci
statist
analys
conduct
review
manag
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
identifi
potenti
elig
studi
exclus
duplic
irrelev
articl
trial
retriev
review
greater
detail
exclud
studi
meet
elig
criteria
thu
includ
trial
review
studi
multicent
random
control
trial
hung
et
al
found
hyperimmun
iv
immunoglobulin
hivig
administr
within
day
symptom
onset
associ
lower
viral
load
reduc
mortal
patient
sever
infect
pilot
studi
insight
ivig
pilot
studi
group
show
hivig
administr
significantli
increas
hemagglutin
inhibit
hai
titer
level
among
patient
influenza
later
perform
intern
doubleblind
rct
shown
hivig
similar
safeti
outcom
death
advers
event
furthermor
beigel
et
al
multicent
phase
trial
found
immun
plasma
provid
support
possibl
benefit
sever
influenza
recent
phase
trial
shown
hightitr
antiinfluenza
plasma
confer
signific
benefit
sever
influenza
tabl
rct
includ
assess
low
risk
bia
respect
attribut
bia
report
bia
select
bia
except
trial
random
sequenc
gener
deem
unclear
phase
trial
beigel
et
al
openlabel
studi
meant
bind
perform
result
high
risk
alloc
conceal
perform
bia
detect
bia
howev
phase
trial
beigel
et
al
multicent
randomis
doubleblind
studi
low
risk
attribut
report
select
bia
trial
davey
jr
et
al
found
low
risk
deal
everi
aspect
trial
extract
data
includ
assess
efficaci
reduc
mortal
sever
influenza
immun
plasma
pool
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
data
show
immun
plasmahivig
signific
differ
reduc
rate
death
compar
placebo
patient
sever
influenza
ci
p
report
hai
titer
level
significantli
increas
patient
infect
influenza
influenza
b
receiv
hivig
howev
hai
titer
level
decreas
gradual
first
week
treatment
tabl
hung
et
al
found
viral
load
significantli
lower
patient
convalesc
plasma
infus
control
group
furthermor
cytokin
includ
tnfa
also
lower
convalesc
plasma
treatment
group
howev
anoth
larg
clinic
trial
overal
viral
load
decreas
hivig
placebo
group
first
day
hivig
group
placebo
group
detect
viru
infus
subgroup
influenza
b
declin
viral
load
greater
hivig
group
placebo
group
addit
signific
differ
influenza
b
viral
load
time
viru
becom
undetect
tabl
trial
hung
et
al
beigel
et
al
found
signific
differ
length
icu
stay
hivigimmun
plasma
treatment
group
control
group
moreov
length
hospit
stay
similar
two
group
addit
day
mechan
ventil
similar
immun
plasma
treatment
standard
care
alon
furthermor
differ
proport
patient
aliv
discharg
day
day
two
group
tabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
advers
event
relat
treatment
report
hung
trial
addit
compar
placebo
hivig
nt
show
seriou
advers
event
fluivig
trial
fewer
particip
immun
plasma
infus
seriou
advers
event
openlabel
rct
later
doubleblind
trial
show
similar
seriou
advers
event
two
group
frequent
acut
respiratori
distress
syndrom
tabl
analys
suggest
convalesc
plasma
may
clinic
relev
impact
reduc
rate
mortal
patient
influenza
also
found
nonsignific
reduct
day
icu
hospit
day
mechan
includ
high
qualiti
rct
convalesc
plasma
hivig
use
sever
influenza
evid
reduct
mortal
associ
convalesc
plasma
strongest
influenza
interpret
appropri
level
caution
limit
sampl
size
earli
use
onset
within
day
addit
pool
data
trail
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
report
death
show
benefit
reduc
mortal
sever
influenza
treatment
secondari
outcom
includ
day
icu
hospit
day
mechan
ventil
rct
report
relev
data
show
nonsignific
reduct
hivigimmun
plasma
group
control
group
b
decreas
influenza
b
viral
load
cytokin
level
clinic
benefit
observ
patient
receiv
hivigimmun
plasma
infus
accord
find
high
qualiti
rct
identifi
passiv
immunotherapi
adjunct
therapi
provid
clinic
benefit
patient
sever
influenza
therefor
patient
clinician
take
previou
find
care
consider
use
convalesc
plasma
critic
ill
infect
patient
composit
plasma
complex
antibodi
produc
human
bodi
match
immun
system
transfus
reaction
may
occur
blood
product
administr
addit
titer
antibodi
convalesc
may
differ
standard
extract
purif
specif
antibodi
may
difficult
time
consum
work
might
suitabl
current
outbreak
final
pilot
studi
control
trial
carri
identifi
optim
time
dosag
indic
use
hivigimmun
plasma
patient
avail
high
qualiti
evid
suggest
convalesc
plasmahivig
safe
unlik
reduc
mortal
patient
sever
influenza
despit
current
outbreak
emerg
affect
public
health
convalesc
plasma
care
taken
consider
welldesign
clinic
trial
carri
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
